Life Sciences

Our Global Life Sciences sector can help you navigate forward and achieve sustainable success in the new health-outcomes-driven ecosystem.

Aging populations and chronic disease are putting pressure on health resources around the world just as scientific progress, augmented intelligence and digital data are transforming the traditional health care models. This is causing a power shift with new entrants (often not driven by profit) disrupting the incumbents.

 

Staying competitive and providing the personalized experience that patients demand require life sciences organizations to find new ways of working. Partnering with others to share data, medicine and resources while anticipating trends and regulatory changes will help ensure sustainability in the increasingly evidence-based, outcomes-focused sector.

 

We help companies across the biotechnology, pharmaceutical and medical technology fields harness this disruption by forming the right alliances, better allocating resources and building trust with customers.

Our Latest thinking

Why licensing deals are a powerful source of growth in life sciences

Innovation is key in Life Sciences. In response to challenges, pharmaceutical companies increasingly turn to external innovation, leveraging licensing deals. Learn more.

03 Oct 2024 Dr. Markus von Minden +1

How implementation unlocks the true potential of AI in pharma

Discover why robust AI implementation is crucial for pharma innovation and how overcoming challenges leads to success.

18 Jul 2024 Patrick Grünewald +1

Life sciences dealmaking in a time of change

Life sciences companies are returning to dealmaking amid cost and revenue pressures – how will they find the right deals to secure value? Learn more.

08 Jan 2024 Subin Baral

How a Danish study unmasks psoriasis wait time

Danish study explores waiting and clinical management times based on real-world data. Read more

04 Dec 2023 Jens Olsen

Supply chain visibility strategic priority for pharma

With digitally driven end-to-end supply chain visibility, pharma companies will be better prepared for the next major supply chain disruption. Learn more.

04 Oct 2023 Derron Stark +1

How digital is changing the tax strategy for MedTech

As MedTech companies make substantial investments in digital technology, there are important tax implications that should be addressed. Learn more.

18 Aug 2023 Ana Maria Romero +2

How early diagnosis can transform health care

Mirxes’ Dr. Zhou Lihan shares his purpose and passion for a more proactive approach to medicine. Learn more.

14 Jun 2023 EY Global

Innovation can utilize data for value-based care

Organizations have the tools to deliver a better personalized health experience, but the ecosystem needs to collaborate to build this future. Learn more.

20 Mar 2023 Pamela Spence

Why life sciences tax departments need to act now on sustainability

Life sciences organizations should consider tax liabilities and compliance obligations resulting from myriad new sustainability taxes. Learn more.

11 Jan 2023 Rick Fonte +2

How do you build future supply chains to best serve patient needs?

In the wake of global disruptions, EY research aims to map out the future for supply chain transformation in the pharmaceutical industry. Read more.

18 Jul 2022 Derron Stark +2

How to navigate global transfer pricing controversy in life sciences

Life sciences companies face growing tax authority scrutiny of their transfer pricing practices and must prepare for escalating controversy.

07 Jun 2022 Rick Fonte

How you can create value in an intelligent health ecosystem

The intelligent health ecosystem will provide smarter insights and personalized health care experiences to patients, anytime and anywhere.

26 May 2022 Pamela Spence

How to navigate EU regulations for drug-device combination products

The new EU Medical Device Regulation (MDR) creates significant regulatory challenges for drug-device combination (DDC) product manufacturers.

10 Mar 2022 EY Global

How one entrepreneur seeks to make affordable health care a reality

Celltrion’s JungJin SEO shares his purpose and passion for more accessible health care. Learn more.

01 Mar 2022 EY Global

How ecosystem participation drives more value for life sciences deals

Biopharmas need to embrace strategic partnerships that share risk and reward to achieve their growth ambitions. Learn more.

10 Jan 2022 Subin Baral

How to account for outcome-based payment arrangements in life sciences

The use of outcome-based payment arrangements in the life sciences sector is growing in many jurisdictions, especially across Europe.

23 Sept 2021 EY Global

Five trends redefining the health sciences and wellness operating model

As demand from consumers accelerates the adoption of new technologies, we explore how companies can provide a more convenient health experience.

19 May 2021 Pamela Spence

How an ‘accidental entrepreneur’ is on a mission to change capitalism

Biocon’s Dr. Kiran Mazumdar-Shaw shares how she overcame challenges to turn a US$500 investment into one of Asia’s leading biotech companies.

19 Oct 2020 EY Global

How biopharmas can create long-term growth focusing on sustainability

In health care, there is a growing need to embed the perspectives of diverse stakeholders in the sustainability agenda.

16 Oct 2020 Pamela Spence

How life sciences companies reassess their supply chains due to COVID-19

The pandemic has shown the strengths and the weaknesses of life sciences supply chains. Now companies must adapt to build future resilience.

18 Sept 2020 EY Global

    Life Sciences 4.0

    When the human body is the biggest data platform, who will capture value?



    Contact us
    Like what you’ve seen? Get in touch to learn more.
    You are visiting EY nordics (en)
    nordics en